Medical Data Infrastructure Provider Yuimedi Raises 200 Million Yen in Second Closing, Total Funding Reaches 600 Million Yen
Yuimedi, a company developing medical data infrastructure, has raised 200 million yen in a second closing of its current funding round from Norinchukin Capital and Darwin Venture Management. This brings the total amount raised to 600 million yen since the first closing in February 2026. The funds will be used to accelerate the expansion of its 'YuiData' real-world data service, its AI-based healthcare platform 'YuiQuery,' and to scale its human resources.
📋 Article Processing Timeline
- 📰 Published: May 26, 2026 at 19:00
- 🔍 Collected: May 26, 2026 at 10:31
- 🤖 AI Analyzed: May 26, 2026 at 11:01 (30 min after Collected)
Yuimedi (Headquarters: Chuo-ku, Tokyo; CEO: Emiri Grimes), a developer of medical data utilization infrastructure, announced the completion of a 200 million yen additional funding round through a third-party allocation of shares, with Norinchukin Capital and Darwin Venture Management as new investors.
This follows the first closing in February 2026, bringing the total funding to 600 million yen.
To achieve its mission of 'delivering necessary medical care to the patients who need it through data,' Yuimedi will leverage these funds to accelerate growth in both business operations and organizational development, including recruitment.
■ Use of Funds
Yuimedi operates three core business segments to become the infrastructure for medical data utilization:
- YuiData Business (Japan): Providing the 'YuiData' real-world data service for pharmaceutical companies, utilizing electronic medical record data from partner institutions.
- YuiQuery Business (US/Japan): Developing and providing a healthcare-focused AI service that allows anyone to conduct medical data research using natural language.
- Medical Data Standardization Business (Japan): Converting real-world data into the global standard OMOP CDM format to promote data utilization.
With this funding, the company plans to invest particularly in the YuiData and YuiQuery businesses.
Specifically, Yuimedi intends to expand its business development, sales, and specialist talent for the YuiData business, and development talent for the YuiQuery business. Yuimedi is actively seeking new team members who resonate with its mission to join them in this challenge.
■ Business Progress
Since the first closing, Yuimedi has announced the following milestones:
- YuiData reached approximately 30 partner hospitals (March 2026)
The number of partner hospitals providing data for the YuiData service has reached approximately 30.
- Technical support for OMOP conversion of NDB/EMR data by NEC (April 2026)
Yuimedi provided technical support for OMOP conversion in a joint research study titled 'Validation of OMOP CDM Conversion Technology for Standardization and Secondary Utilization of Medical Information,' conducted with NEC Corporation, Ehime University, and the Federation of Medical Data Networking and Analysis (FedAna). This is part of the initiatives toward realizing the government's 'National Healthcare Information Platform Concept' and the 'Japanese EHDS.'
This follows the first closing in February 2026, bringing the total funding to 600 million yen.
To achieve its mission of 'delivering necessary medical care to the patients who need it through data,' Yuimedi will leverage these funds to accelerate growth in both business operations and organizational development, including recruitment.
■ Use of Funds
Yuimedi operates three core business segments to become the infrastructure for medical data utilization:
- YuiData Business (Japan): Providing the 'YuiData' real-world data service for pharmaceutical companies, utilizing electronic medical record data from partner institutions.
- YuiQuery Business (US/Japan): Developing and providing a healthcare-focused AI service that allows anyone to conduct medical data research using natural language.
- Medical Data Standardization Business (Japan): Converting real-world data into the global standard OMOP CDM format to promote data utilization.
With this funding, the company plans to invest particularly in the YuiData and YuiQuery businesses.
Specifically, Yuimedi intends to expand its business development, sales, and specialist talent for the YuiData business, and development talent for the YuiQuery business. Yuimedi is actively seeking new team members who resonate with its mission to join them in this challenge.
■ Business Progress
Since the first closing, Yuimedi has announced the following milestones:
- YuiData reached approximately 30 partner hospitals (March 2026)
The number of partner hospitals providing data for the YuiData service has reached approximately 30.
- Technical support for OMOP conversion of NDB/EMR data by NEC (April 2026)
Yuimedi provided technical support for OMOP conversion in a joint research study titled 'Validation of OMOP CDM Conversion Technology for Standardization and Secondary Utilization of Medical Information,' conducted with NEC Corporation, Ehime University, and the Federation of Medical Data Networking and Analysis (FedAna). This is part of the initiatives toward realizing the government's 'National Healthcare Information Platform Concept' and the 'Japanese EHDS.'
FAQ
Yuimediが今回調達した金額はいくらですか？
今回（セカンドクローズ）は2億円を調達し、本年2月のファーストクローズと合わせた総額は6億円です。
今回の資金調達の主な引受先はどこですか？
農林中金キャピタル株式会社と、台湾のDarwin Venture Management（達盈管理顧問股份有限公司）です。
Yuimediの主な事業内容は？
電子カルテデータを用いた製薬企業向けリアルワールドデータ活用サービス「YuiData」、ヘルスケア特化型AIサービス「YuiQuery」、およびOMOP CDMへのデータ標準化事業を展開しています。
調達した資金の主な使途は何ですか？
主に「YuiData」事業における事業開発・セールスおよび専門職人材の採用、また「YuiQuery」事業における開発人材の拡充に充てられます。
Yuimediの直近の事業進捗について教えてください。
データ提供協力病院数が約30施設に達したほか、NECや愛媛大学らと共同で医療情報標準化（OMOP CDM変換）技術検証を実施しました。